Comparing the current results to its competitors, Dmk Pharmaceuticals reported Revenue decrease in the 3 quarter 2023 year on year by -99.4 %, faster than the overall decrease of Dmk Pharmaceuticals's competitors by -7.31 %, recorded in the same quarter.
Dmk Pharmaceuticals Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 3.18 %
December 21, 2023
DMK Pharmaceuticals Secures Full Rights to Commercialize ZIMHI and Seeks Lucrative PartnershipsIn a strategic move to expand revenue generation, DMK Pharmaceuticals has successfully regained full rights to commercialize their highly anticipated product, ZIMHI. This significant development allows the company to establish a stronger foothold in the pharmaceutical market and pursue commercialization partnerships in the United States, Canada, and Europe. ZIMHI, a groundbreaking medical innovation, holds enormous potential in revolutionizing healthcare practices. With its unique features and promising results, DMK Pharmaceuticals aims to maximize ZIMHI s market reach through strategic collaborations with industry...
Publicly Traded Peers of Dmk Pharmaceuticals Corporation
Mirati Therapeutics Inc Share Performance
+22.52%
One Year
Mirati Therapeutics Inc
Profile
Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.
Kiniksa Pharmaceuticals International Plc Share Performance
-1.15%
Over The Past 5 Days
Kiniksa Pharmaceuticals International Plc
Profile
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with debilitating diseases and unmet medical needs. Their business model revolves around identifying potential drug candidates, conducting rigorous research and development, and ultimately bringing these drugs to market to provide innovative treatment options. They generate revenue through the sale of their products and collaborations with other companies for the development and commercialization of their therapies.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Sources:
Dmk Pharmaceuticals Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dmk Pharmaceuticals Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
